Massimo Loda
Impact in
- Cancer Research top 0.02%
- Cancer, Lipids, and Metabolism
- Oncology top 0.05%
- Cancer-related Molecular Pathways
Papers in
-
- Ubiquitin and proteasome pathways 33
- Epigenetics and DNA Methylation 33
-
- Prostate Cancer Treatment and Research 108
- Prostate Cancer Diagnosis and Treatment 36
- Co-authors
- Sabina Signoretti (45 shared papers)William R. Sellers (16 shared papers)Todd R. Golub (13 shared papers)Shuji Ogino (22 shared papers)Charles S. Fuchs (20 shared papers)Eric S. Lander (3 shared papers)Phillip G. Febbo (13 shared papers)Christine Ladd (3 shared papers)
- Journals
- Cancer Research (27 papers)Journal of Clinical Oncology (25 papers)Clinical Cancer Research (24 papers)Molecular Cancer Research (15 papers)Cancer Epidemiology Biomarkers & Prevention (14 papers)
- Partner nations
- United StatesItalyUnited Kingdom
In The Last Decade
Massimo Loda
460 papers receiving 39.7k citations
Massimo Loda's Hit Papers
Peers
Comparison fields: 5 of 194
- Cancer Research 9.0k
- Oncology 10.1k
- Molecular Biology 20.2k
- Pulmonary and Respiratory Medicine 8.1k
- Pathology and Forensic Medicine 4.2k
Countries citing papers authored by Massimo Loda
This map shows the geographic impact of Massimo Loda's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Massimo Loda with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Massimo Loda more than expected).
Fields of papers citing papers by Massimo Loda
This network shows the impact of papers produced by Massimo Loda. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Massimo Loda. The network helps show where Massimo Loda may publish in the future.
Co-authors
The 25 scholars most cited alongside Massimo Loda, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 470 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses Hit paper breakdown → | 2001 | 1954 |
| 2 | Gene expression correlates of clinical prostate cancer behavior Hit paper breakdown → | 2002 | 1833 |
| 3 | Multiclass cancer diagnosis using tumor gene expression signatures Hit paper breakdown → | 2001 | 1461 |
| 4 | Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines. Hit paper breakdown → | 1997 | 1203 |
| 5 | Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas Hit paper breakdown → | 1997 | 911 |
| 6 | mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways Hit paper breakdown → | 2004 | 781 |
| 7 | Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance Hit paper breakdown → | 2017 | 696 |
| 8 | Control of TH2 polarization by the chemokine monocyte chemoattractant protein-1 Hit paper breakdown → | 2000 | 688 |
| 9 | CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer Hit paper breakdown → | 2008 | 596 |
| 10 | Prostate stem cell antigen: A cell surface marker overexpressed in prostate cancer Hit paper breakdown → | 1998 | 559 |
| 11 | Essential roles of PI(3)K–p110β in cell growth, metabolism and tumorigenesis Hit paper breakdown → | 2008 | 559 |
| 12 | Inappropriate expression of hepcidin is associated with iron refractory anemia: implications for the anemia of chronic disease Hit paper breakdown → | 2002 | 514 |
| 13 | Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage. | 1999 | 499 |
| 14 | 2000 | 492 | |
| 15 | 2000 | 463 | |
| 16 | 1995 | 456 | |
| 17 | 2010 | 451 | |
| 18 | Lipids and cancer: Emerging roles in pathogenesis, diagnosis and therapeutic intervention Hit paper breakdown → | 2020 | 430 |
| 19 | 2005 | 403 | |
| 20 | Prognostic role of the cyclin-dependent kinase inhibitor p27 in non-small cell lung cancer. | 1997 | 381 |
About Massimo Loda
Massimo Loda is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine, Cancer Research, Oncology and Surgery, having authored 470 papers that have together received 40.5k indexed citations. Recurring topics across this work include Prostate Cancer Treatment and Research (108 papers), Cancer, Lipids, and Metabolism (76 papers), Cancer-related Molecular Pathways (44 papers), Prostate Cancer Diagnosis and Treatment (36 papers), Ubiquitin and proteasome pathways (33 papers), Epigenetics and DNA Methylation (33 papers), Genetic factors in colorectal cancer (28 papers) and Cancer Genomics and Diagnostics (26 papers). The work is most often cited by research in Cancer Research (9.0k citations), Oncology (10.1k citations), Molecular Biology (20.2k citations), Pulmonary and Respiratory Medicine (8.1k citations) and Pathology and Forensic Medicine (4.2k citations). Massimo Loda has collaborated with scholars based in United States, Italy and United Kingdom. Frequent co-authors include Sabina Signoretti, William R. Sellers, Todd R. Golub, Shuji Ogino, Charles S. Fuchs, Eric S. Lander, Phillip G. Febbo, Christine Ladd, Giorgia Zadra and Michele Pagano. Their work appears in journals such as Cancer Research, Journal of Clinical Oncology, Clinical Cancer Research, Molecular Cancer Research and Cancer Epidemiology Biomarkers & Prevention.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.